Browsing by Author "Ozakbas, S."

Now showing 1 - 7 of 7

Cognition as a Parameter in Monitoring the Effect of Multiple Sclerosis Relapse Treatment: a Prospective Controlled Study
(Elsevier, 2024) Cinar, B. Piri; Baba, C.; Demir, S.; Uzunkopru, C.; Seferoglu, M.; Dogan, I. Gungor; Ozakbas, S.
Background: Cognitive evaluation was considered to be very important in the relapse period, on the basis of the presence of isolated cognitive attacks and the necessity of monitoring the patient both physically and cognitively. Materials and methods: People with MS (pwMS) who were hospitalized during relapse were included in the study. All MS patients were evaluated by the neurologist with Expanded Disability Status Scale (EDSS), The 9 Hole Peg Test (9HPT) and the Timed 25-Foot Walk Test (T25-FWT). Additionally, all participants were examined cognitively with the Turkish version of the Brief International Cognitive Assessment for MS (BICAMS) battery. Also, schedules were indicated as during relapse before the treatment (pre-treatment) and the first month after relapse (1-month follow-up). Results: A total of 140 MS patients (mean age; 34.98 +/- 10.09, mean disease duration; 6.05 +/- 5.29 years) and 86 healthy controls (mean age; 36.94 +/- 10.83) were included to the present study. The mean EDSS scores in pretreatment in MS patients was 2.74 +/- 1.14 and decreased significantly in the 1-month follow-up (1.74 +/- 1.24; p<0.001). The mean SDMT score was lower by 8.76 points in MS patients than in HCs) in pre-treatment and 7.66 points in 1-month follow-up (p<0.001). The mean SDMT scores of all participants increased with measurement time gradually (p<0.001). Conclusion: In this study, it was detected which cognitive domains were affected after relapse treatment and cognitive changes in pwMS during relapse and remission periods compared to the healthy controls. All three BICAMS test scores significantly increased in one-month follow-up than the pre-treatment period. The results showed that CVLT-II and BVMT-R scores improved more in pwMS than in HCs, and also SDMT scores of pwMS showed a trend of increase, but was not a significant improvement.
Cognition as a Parameter That Should Not Be Ignored When Evaluating the Effect of Relapse Treatment: a Prospective Controlled Study
(Sage Publications Ltd, 2021) Cinar, B.; Baba, C.; Demir, S.; Uzunkopru, C.; Seferoglu, M.; Gungor Dogan, I.; Ozakbas, S.
Feasibility of Exergaming for Upper Extremity Rehabilitation in People With Multiple Sclerosis
(Sage Publications Ltd, 2023) Ozdogar, A. T.; Emec, M.; Kaya, E.; Karakas, H.; Dastan, S.; Kahraman, T.; Ozakbas, S.
Feasibility of Exergaming for Upper Extremity Rehabilitation in People With Multiple Sclerosis: Prospective Clinical Trial
(Springer Heidelberg, 2024) Ozdogar, A. T.; Emec, M.; Kaya, E.; Karakas, H.; Dastan, S.; Kahraman, T.; Ozakbas, S.
BackgroundExergaming has been suggested as a rehabilitation method since it is more motivational for people with multiple sclerosis (MS, pwMS). However, the major disadvantage of this method is the lack of specific scenarios designed for pwMS.ObjectivesThis study aims to assess the feasibility of exergaming, which was developed for pwMS.MethodsThis unblinded prospective clinical trial was performed in the outpatient MS Clinic of Dokuz Eyl & uuml;l University Hospital. Exergaming scenarios were developed in collaboration with medical personnel consisting of physiotherapists and doctors, and computer engineers. A total of 30 participants who had definite MS diagnoses were included. The exergaming scenarios were implemented using the Microsoft Kinect. A physiotherapist applied custom-made exergames for one session. All the participants were assessed immediately after the session. The User Satisfaction Evaluation Questionnaire was used to assess the user's satisfaction with the system and exergaming.ResultsThe mean age was 41.5, the mean Expanded Disability Status Scale was 4.5 (range between 0 and 7), and the mean disease duration was 10.0 years. Twenty patients were relapsing-remitting, and 10 were secondary-progressive. The mean scores of the User Satisfaction Evaluation Questionnaire were 4.33 (SD = 0.84) for helpfulness for rehabilitation, 1.63 (SD = 1.1) for not disturbing, 4.50 (SD = 1.07) for understandability, 4.0 (SD = 0.91) for easiness to control, and 4.33 (SD = 0.84) for enjoyability.ConclusionThese results showed that our custom-made exergaming scenario could be feasible in upper extremity rehabilitation in MS. More research is needed to investigate its effectiveness in the rehabilitation of upper limbs.
Is Disease-Modifying Therapy Use in Multiple Sclerosis a Risk Factor During the Covid-19 Pandemic? a Large Cohort Study
(Pro Medicina Foundation, 2024) Ozakbas, S.; Baba, C.; Yavas, I.; Samadzade, U.; Ozdogar, A.T.
Objective: This study aims to investigate the relationship between disease-modifying therapies (DMTs) used in people with MS (pwMS) and the risk of COVID-19 in-fection. Methods: This longitudinal cohort study included the MS cohort of 3402 people followed for COVID-19 infection. The whole MS cohort was interviewed at least once for information about COVID-19. A semi-structured interview was developed and performed by a team consisting of a medical doctor, nurse, and physiotherapist. Clinical information was obtained from the patient's medical records. This study was approved by the Noninvasive Research Ethics Board (Date: 08.09.2021, Decision No: 2021/25-06). Results: Of the 487 pwMS infected with COVID-19, 35 reported reinfections. The major differences regarding DMT between pwMS with and without COVID-19 infection were observed for fingolimod, ocrelizumab, and azathioprine. Forty-three (8.9%) people experienced the COVID-19 infection severely or critically; 12 (37.5%) had MS treatment with ocrelizumab. Fifty percent of pwMS who were treated in intensive care (7/14 patients) and died (3/6 patients) were being treated with ocrelizumab. As a result of regression analysis, being younger and using di-methyl fumarate, fingolimod, ocrelizumab, and cladrib-ine DMTs were the main factors associated with having COVID-19 infection group. Conclusions: Current results show that disability due to MS and increased disease duration are not risk factors for COVID-19 infection, while age is negatively associated with contracting COVID-19 infection. These results show no relationship between the MS clinic and COVID-19 in-fection. We have found that using certain DMTs in pwMS increases the risk of contracting COVID-19 infection. © 2024 PRO MEDICINA Foundation,41 Published by PRO MEDICINA Foundation.
Real World Efficacy and Safety of Teriflunomide in Multiple Sclerosis: an Observational Study With Four Years Follow-Up
(Sage Publications Ltd, 2019) Boz, C.; Terzi, M.; Ozakbas, S.; Yuceyar, N.; Efendi, H.; Balci, B. P.; Kizilay, F.
Real World Efficacy and Safety of Teriflunomide in Patients With Relapsing-Remitting Multiple Sclerosis
(Sage Publications Ltd, 2017) Boz, C.; Ozakbas, S.; Terzi, M.; Turkoglu, R.; Akman, G.; Efendi, H.; Altunrende, B.